<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">5x4NjhJCQ9fZpKDMQSpb7Ms</article-id>
      <article-id pub-id-type="other">00010</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000900010</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09700110</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000056</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Insufici&#234;ncia card&#237;aca: compara&#231;&#227;o entre o teste de caminhada de seis minutos e o teste cardiopulmonar</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Eduardo Elias Vieira de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Daniela Caetano</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cresc&#234;ncio</surname>
            <given-names>J&#250;lio C&#233;sar</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santi</surname>
            <given-names>Giovani Luiz De</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Papa</surname>
            <given-names>Val&#233;ria</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Marques</surname>
            <given-names>Fabiana</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schmidt</surname>
            <given-names>Andr&#233;</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Marin-Neto</surname>
            <given-names>Jos&#233; Antonio</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sim&#245;es</surname>
            <given-names>Marcus Vin&#237;cius</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gallo Junior</surname>
            <given-names>Louren&#231;o</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina de Ribeir&#227;o Preto </institution>
        <institution content-type="orgdiv2">Divis&#227;o de Cardiologia</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Ribeir&#227;o Preto</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina de Ribeir&#227;o Preto </institution>
        <institution content-type="orgdiv2">Divis&#227;o de Cardiologia</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>07</month>
        <year>2011</year>
      </pub-date>
      <volume>97</volume>
      <issue>1</issue>
      <fpage>59</fpage>
      <lpage>64</lpage>
      <history>
        <date date-type="rev-recd">
          <day>01</day>
          <month>12</month>
          <year>2010</year>
        </date>
        <date date-type="received">
          <day>21</day>
          <month>07</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>01</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A insufici&#234;ncia card&#237;aca cr&#244;nica (IC) &#233; uma s&#237;ndrome complexa caracterizada pela redu&#231;&#227;o do d&#233;bito card&#237;aco em rela&#231;&#227;o &#224;s necessidades metab&#243;licas do organismo, bem como altera&#231;&#245;es metab&#243;licas e do eixo neuro-hormonal. Sintomas como fadiga muscular e dispneia s&#227;o not&#243;rios e os testes de esfor&#231;o s&#227;o amplamente utilizados para a avalia&#231;&#227;o da capacidade funcional, progn&#243;stico e efic&#225;cia das interven&#231;&#245;es terap&#234;uticas nessa s&#237;ndrome. OBJETIVO: Avaliar a reprodutibilidade do teste de caminhada de seis minutos (TC6') em pacientes com IC e correlacionar a magnitude das vari&#225;veis atingidas no pico do esfor&#231;o do TC6' com as de um teste cardiopulmonar (TCP). M&#201;TODOS: Foram estudados 16 pacientes (12 homens e 4 mulheres) com diagn&#243;stico de IC CF I-II (NYHA). Os volunt&#225;rios foram submetidos a dois testes TC6' (TC6'1 e TC6'2) com intervalo de 30 minutos entre eles; posteriormente realizaram um TCP m&#225;ximo. RESULTADOS: Todas as vari&#225;veis obtidas nos dois TC6' mostraram-se significantes, com altas correla&#231;&#245;es: dist&#226;ncia percorrida (DP) (r = 0,93; p &lt; 0,0001), frequ&#234;ncia card&#237;aca (FC) (r = 0,89; p &lt; 0,0001), consumo de oxig&#234;nio (VO2) (r = 0,93; p &lt; 0,0001) e escala de percep&#231;&#227;o de esfor&#231;o (r = 0,85; p &lt; 0,0001). Por sua vez, todas as vari&#225;veis analisadas no TC6' mostraram correla&#231;&#245;es moderadas e significantes com as vari&#225;veis obtidas no TCP, a saber: FC pico (r = 0,66; p = 0,005); VO2 (r = 0,57; p = 0,02) e VO2 no TCP e DP no TC6'2 (r = 0,70; p = 0,002). CONCLUS&#195;O: O TC6' foi reprodut&#237;vel nesse grupo de pacientes com IC (NYHA - I-II) e se correlacionou com o TCP. Sendo assim, apresenta-se como ferramenta de avalia&#231;&#227;o fidedigna, constituindo-se numa alternativa adequada, segura e de baixo custo para a prescri&#231;&#227;o de exerc&#237;cios f&#237;sicos aer&#243;bicos em pacientes com IC.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Insufici&#234;ncia card&#237;aca</kwd>
        <kwd>exerc&#237;cio</kwd>
        <kwd>caminhada</kwd>
        <kwd>testes de fun&#231;&#227;o respirat&#243;ria</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>06</day>
        <month>05</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>Insufici&#234;ncia card&#237;aca: compara&#231;&#227;o entre o teste de caminhada de seis minutos e o teste cardiopulmonar</bold>
    </p>
    <p>
      <bold>Eduardo Elias Vieira de Carvalho<sup>I</sup>; Daniela Caetano Costa<sup>I</sup>; J&#250;lio C&#233;sar Cresc&#234;ncio<sup>I</sup>; Giovani Luiz De Santi<sup>I</sup>; Val&#233;ria Papa<sup>I</sup>; Fabiana Marques<sup>I</sup>; Andr&#233; Schmidt<sup>II</sup>; Jos&#233; Antonio Marin-Neto<sup>II</sup>; Marcus Vin&#237;cius Sim&#245;es<sup>II</sup>; Louren&#231;o Gallo Junior<sup>I</sup></bold>
    </p>
    <p><sup>I</sup>Laborat&#243;rio de Fisiologia do Exerc&#237;cio - Departamento de Cl&#237;nica M&#233;dica - Divis&#227;o de Cardiologia - Faculdade de Medicina de Ribeir&#227;o Preto - USP </p>
    <p><sup>II</sup>Departamento de Cl&#237;nica M&#233;dica - Divis&#227;o de Cardiologia - Faculdade de Medicina de Ribeir&#227;o Preto - USP, Ribeir&#227;o Preto, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="ad">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A insufici&#234;ncia card&#237;aca cr&#244;nica (IC) &#233; uma s&#237;ndrome complexa caracterizada pela redu&#231;&#227;o do d&#233;bito card&#237;aco em rela&#231;&#227;o &#224;s necessidades metab&#243;licas do organismo, bem como altera&#231;&#245;es metab&#243;licas e do eixo neuro-hormonal. Sintomas como fadiga muscular e dispneia s&#227;o not&#243;rios e os testes de esfor&#231;o s&#227;o amplamente utilizados para a avalia&#231;&#227;o da capacidade funcional, progn&#243;stico e efic&#225;cia das interven&#231;&#245;es terap&#234;uticas nessa s&#237;ndrome. </p>
    <p><bold>OBJETIVO:</bold> Avaliar a reprodutibilidade do teste de caminhada de seis minutos (TC6') em pacientes com IC e correlacionar a magnitude das vari&#225;veis atingidas no pico do esfor&#231;o do TC6' com as de um teste cardiopulmonar (TCP). </p>
    <p><bold>M&#201;TODOS:</bold> Foram estudados 16 pacientes (12 homens e 4 mulheres) com diagn&#243;stico de IC CF I-II (NYHA). Os volunt&#225;rios foram submetidos a dois testes TC6' (TC6'1 e TC6'2) com intervalo de 30 minutos entre eles; posteriormente realizaram um TCP m&#225;ximo. </p>
    <p><bold>RESULTADOS:</bold> Todas as vari&#225;veis obtidas nos dois TC6' mostraram-se significantes, com altas correla&#231;&#245;es: dist&#226;ncia percorrida (DP) (r = 0,93; p &lt; 0,0001), frequ&#234;ncia card&#237;aca (FC) (r = 0,89; p &lt; 0,0001), consumo de oxig&#234;nio (VO<sub>2</sub>) (r = 0,93; p &lt; 0,0001) e escala de percep&#231;&#227;o de esfor&#231;o (r = 0,85; p &lt; 0,0001). Por sua vez, todas as vari&#225;veis analisadas no TC6' mostraram correla&#231;&#245;es moderadas e significantes com as vari&#225;veis obtidas no TCP, a saber: FC pico (r = 0,66; p = 0,005); VO<sub>2</sub> (r = 0,57; p = 0,02) e VO<sub>2</sub> no TCP e DP no TC6'2 (r = 0,70; p = 0,002). </p>
    <p><bold>CONCLUS&#195;O:</bold> O TC6' foi reprodut&#237;vel nesse grupo de pacientes com IC (NYHA - I-II) e se correlacionou com o TCP. Sendo assim, apresenta-se como ferramenta de avalia&#231;&#227;o fidedigna, constituindo-se numa alternativa adequada, segura e de baixo custo para a prescri&#231;&#227;o de exerc&#237;cios f&#237;sicos aer&#243;bicos em pacientes com IC.</p>
    <p><bold>Palavras-chave:</bold> Insufici&#234;ncia card&#237;aca, exerc&#237;cio, caminhada, testes de fun&#231;&#227;o respirat&#243;ria.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A insufici&#234;ncia card&#237;aca cr&#244;nica (IC) &#233; a via final comum da maioria das cardiopatias. Trata-se de uma s&#237;ndrome cl&#237;nica complexa, caracterizada pela incapacidade do cora&#231;&#227;o em gerar d&#233;bito card&#237;aco em n&#237;veis capazes de atender &#224;s necessidades metab&#243;licas do organismo<sup>1</sup>, associada a dist&#250;rbios metab&#243;licos, inflamat&#243;rios e ativa&#231;&#227;o neuro-hormonal<sup>2</sup>. Representa importante problema de sa&#250;de p&#250;blica, considerando-se a preval&#234;ncia crescente e os &#237;ndices de hospitaliza&#231;&#227;o associados &#224; alta morbimortalidade. Os avan&#231;os cient&#237;ficos e tecnol&#243;gicos e as melhores condi&#231;&#245;es socioecon&#244;micas t&#234;m propiciado aumento da longevidade da popula&#231;&#227;o geral e tamb&#233;m dos cardiopatas, fator associado ao aumento acentuado da incid&#234;ncia de IC no Brasil e no mundo<sup>3</sup>.</p>
    <p>Usualmente, os pacientes com IC apresentam exacerba&#231;&#227;o dos sintomas durante o esfor&#231;o e a medida da toler&#226;ncia ao exerc&#237;cio &#233; utilizada para avaliar a sua capacidade funcional, que se correlaciona com a gravidade da disfun&#231;&#227;o card&#237;aca. Dessa forma, o emprego do teste de esfor&#231;o para mensura&#231;&#227;o objetiva da capacidade funcional &#233; valioso instrumento para estratifica&#231;&#227;o do progn&#243;stico dos pacientes com insufici&#234;ncia card&#237;aca<sup>4,5</sup>. Nesse contexto, o teste de esfor&#231;o cardiopulmonar (TCP) tem se estabelecido como o padr&#227;o de refer&#234;ncia.</p>
    <p>O teste de caminhada de seis minutos (TC6'), pela sua ampla disponibilidade, seguran&#231;a e facilidade de execu&#231;&#227;o, est&#225; sendo utilizado, cada vez mais, como uma alternativa ao TCP para avaliar a capacidade funcional de pacientes com IC<sup>5-8</sup>. Ele &#233; considerado um esfor&#231;o subm&#225;ximo que mimetiza as atividades di&#225;rias e &#233;, geralmente, bem tolerado pelos pacientes. Ressalte-se que a dist&#226;ncia percorrida durante o TC6' &#233; um preditor independente de mortalidade e reinterna&#231;&#245;es em pacientes com IC<sup>3,9,10</sup>. Adicionalmente, o aumento da dist&#226;ncia percorrida em seis minutos tem-se mostrado um &#237;ndice sens&#237;vel para avaliar a resposta a interven&#231;&#245;es terap&#234;uticas na IC<sup>11</sup>.</p>
    <p>Apesar da sua ampla utiliza&#231;&#227;o, ainda h&#225; controv&#233;rsia se os resultados obtidos no TC6' apresentam adequada correla&#231;&#227;o com aqueles originados do TCP, em pacientes com diferente gravidade da s&#237;ndrome de IC<sup>12</sup>. Portanto, o objetivo do presente estudo foi avaliar a reprodutibilidade do TC6' e comparar os resultados dos &#237;ndices de avalia&#231;&#227;o da capacidade funcional obtidos no TC6' com os do TCP, em pacientes com IC cr&#244;nica n&#227;o avan&#231;ada.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>Os pacientes inclu&#237;dos neste estudo foram selecionados a partir da casu&#237;stica de um projeto anteriormente conduzido na nossa Institui&#231;&#227;o, cujo objetivo principal foi avaliar a reserva contr&#225;til em pacientes com IC de etiologia n&#227;o isqu&#234;mica. Naquele estudo original foram prospectivamente investigados 30 pacientes com IC classe funcional I - III (NYHA). Os pacientes encontravam-se clinicamente est&#225;veis, em uso de terapia medicamentosa devidamente otimizada, e em seguimento cl&#237;nico ambulatorial na cl&#237;nica de IC da nossa Institui&#231;&#227;o. Dentre esses pacientes, foram identificados aqueles cujos dados existentes dos TCP e TC6' puderam ser recuperados dos respectivos sistemas de processamento e an&#225;lise. Dessa forma, foram identificados 16 pacientes (12 homens e 4 mulheres), com idade m&#233;dia (&#177; DP) de 57,5 (&#177; 10,1) anos, com diagn&#243;stico de IC classe funcional I-II (NYHA). Todos eles tinham participado voluntariamente do estudo, cujas principais caracter&#237;sticas antropom&#233;tricas, cl&#237;nicas e laboratoriais encontram-se resumidas na tabela 1.</p>
    <p>Na ocasi&#227;o da realiza&#231;&#227;o dos testes, todos assinaram o termo de consentimento livre e esclarecido, e o estudo foi aprovado pelo Comit&#234; de &#201;tica em Pesquisa do HCFMRP - USP.</p>
    <p>Teste de caminhada e teste cardiopulmonar</p>
    <p>Ap&#243;s avalia&#231;&#227;o cl&#237;nica criteriosa e inclus&#227;o no estudo, os pacientes realizaram primeiramente o TC6' e, no prazo m&#225;ximo de uma semana, foram submetidos ao TCP. Essa janela temporal estreita visa limitar a eventual influ&#234;ncia de mudan&#231;as do estado cl&#237;nico e da gravidade dos sintomas sobre os resultados dos testes de avalia&#231;&#227;o da capacidade funcional. Todos os testes foram realizados no per&#237;odo da manh&#227; para uniformizar as influ&#234;ncias das varia&#231;&#245;es circadianas da frequ&#234;ncia card&#237;aca (FC) e das demais vari&#225;veis cardiorrespirat&#243;rias.</p>
    <p>Os TC6' foram aplicados pelos mesmos examinadores em um corredor de 30 metros, com marca&#231;&#245;es a cada 5 metros, para exata determina&#231;&#227;o da dist&#226;ncia percorrida<sup>13</sup>. Os pacientes foram monitorizados pelo cardiofrequenc&#237;metro Polar<sup>&#174;</sup> S810, com registro instant&#226;neo e armazenamento dos valores de FC; os valores da press&#227;o arterial foram obtidos pelo m&#233;todo auscultat&#243;rio (esfigmoman&#244;metro aneroide) antes do teste, imediatamente ap&#243;s o t&#233;rmino, no segundo e no quarto minutos de recupera&#231;&#227;o, e o &#237;ndice de percep&#231;&#227;o da intensidade de esfor&#231;o de Borg (CR10) foi obtido no in&#237;cio e no final do teste. A FC pico foi obtida na an&#225;lise posterior dos dados armazenados pelo <italic>software</italic> POLAR<sup>&#174;</sup> Precision Performance SW.</p>
    <p>Os pacientes foram orientados a andar numa velocidade m&#225;xima durante os seis minutos do teste (TC6'1); se necess&#225;rio eles poderiam parar para descansar e em seguida retomar ao teste. Os examinadores utilizaram frases de incentivo para que os pacientes mantivessem o mesmo ritmo de caminhada at&#233; o final do teste, e ao final de seis minutos foi medida a dist&#226;ncia percorrida (DP). Ap&#243;s um intervalo m&#237;nimo de 30 minutos e m&#225;ximo de 45 minutos, os pacientes repetiram o teste de caminhada (TC6'2), seguindo o mesmo m&#233;todo.</p>
    <p>O c&#225;lculo do consumo de oxig&#234;nio (VO<sub>2</sub>) estimado para o teste de caminhada foi realizado mediante uma f&#243;rmula publicada anteriormente<sup>10</sup>.</p>
    <p>Todos os volunt&#225;rios estudados foram submetidos a uma prova ergoespirom&#233;trica m&#225;xima. O protocolo consistiu na realiza&#231;&#227;o de esfor&#231;o f&#237;sico din&#226;mico na posi&#231;&#227;o sentada, em cicloerg&#244;metro de frenagem eletromagn&#233;tica (Corival 400, Quinton). A pot&#234;ncia aplicada no cicloerg&#244;metro foi do tipo rampa, com intensidade determinada segundo f&#243;rmula desenvolvida por Wasserman e cols.<sup>14</sup>, baseada em caracter&#237;sticas antropom&#233;tricas, idade e g&#234;nero. Os pacientes foram incentivados a realizar o esfor&#231;o aplicado at&#233; a pot&#234;ncia em que atingissem a exaust&#227;o cardiorrespirat&#243;ria. Em todos os pacientes estudados, o in&#237;cio da rampa foi precedido de um esfor&#231;o com carga m&#237;nima (3-4 Watts) na velocidade constante de 60 rota&#231;&#245;es por minuto, com o objetivo de obter-se um aquecimento pr&#233;vio dos sistemas fisiol&#243;gicos envolvidos no transporte de oxig&#234;nio. As vari&#225;veis ventilat&#243;rias foram obtidas nesse protocolo usando-se um ergoespir&#244;metro (CPX/D MedGraphics), que permite aquisi&#231;&#227;o, processamento e armazenamento dos dados de respira&#231;&#227;o a respira&#231;&#227;o. Os valores-pico de VO<sub>2</sub> e FC foram expressos como m&#233;dia dos &#250;ltimos 30 segundos de registro, e foram os escolhidos para ser comparados com a dist&#226;ncia percorrida e o VO<sub>2</sub> inferido no TC6'.</p>
    <p>Para an&#225;lise da correla&#231;&#227;o entre o TC6' e o TCP, optou-se por utilizar o TC6'2, uma vez que, no segundo teste, espera-se que os pacientes estejam mais bem familiarizados com a metodologia e possam realiz&#225;-lo com maior dom&#237;nio e seguran&#231;a da t&#233;cnica.</p>
    <p>An&#225;lise estat&#237;stica</p>
    <p>Os dados foram expressos em valores de m&#233;dia &#177; desvio padr&#227;o. A an&#225;lise estat&#237;stica foi realizada usando o teste n&#227;o param&#233;trico de correla&#231;&#227;o de Spearman. O n&#237;vel de signific&#226;ncia estat&#237;stica foi de 5%.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Os dados de correla&#231;&#227;o entre os TC6'1 e TC6'2 est&#227;o apresentados na <xref ref-type="fig" rid="aop04811fig01">figura 1</xref>. A DP mostrou valor do coeficiente de correla&#231;&#227;o alto, e estatisticamente significante entre TC6'1 e TC6'2 (545,47 &#177; 74,49 m e 550,31 &#177; 66,40 m, respectivamente) (r = 0,93; p &lt; 0,0001, <xref ref-type="fig" rid="aop04811fig01">figura 1A</xref>). A resposta da FC pico, medida atrav&#233;s do cardiofrequenc&#237;metro no final do sexto minuto de cada teste (128 &#177; 24 bpm para TC6'1 e 129 &#177; 25 bpm para TC6'2), tamb&#233;m apresentou correla&#231;&#227;o significativa (r = 0,89; p &lt; 0,0001, <xref ref-type="fig" rid="aop04811fig01">figura 1B</xref>). De forma semelhante, o VO<sub>2</sub>pico, estimado nos TC6'1 e TC6'2 (20,34 &#177; 2,23 ml/kg/min; 20,49 &#177; 1,99 ml/kg/min, respectivamente) apresentou valor de correla&#231;&#227;o alto e significante (r = 0,93; p &lt; 0,0001, <xref ref-type="fig" rid="aop04811fig01">figura 1C</xref>). Finalmente, a intensidade de percep&#231;&#227;o do esfor&#231;o ao final de cada teste (4,5 &#177; 1,7 e 4,8 &#177; 1,7 para TC6'1 e TC6'2, respectivamente), avaliado pela escala de Borg, tamb&#233;m mostrou uma alta e significante correla&#231;&#227;o (r = 0,85; p &lt; 0,0001, <xref ref-type="fig" rid="aop04811fig01">figura 1D</xref>).</p>
    <p><fig id="aop04811fig01"/>&#13;
&#160;&#13;
&#160;&#13;
</p>
    <p>
      <fig id="aop04811fig01ab">
        <graphic xlink:href="1678-4170-abc-97-01-0059-00056-gf01.jpg"/></fig>
    </p>
    <p>&#13;
  <fig id="aop04811fig01xcd"/><fig id="aop04811fig01cd"><graphic xlink:href="1678-4170-abc-97-01-0059-00056-gf02.jpg"/></fig></p>
    <p>A <xref ref-type="fig" rid="aop04811fig02">figura 2</xref> ilustra os par&#226;metros correlacionados entre o TC6'2 e o TCP. A rela&#231;&#227;o da FC pico do TC6'2 e do TCP (129 &#177; 25 bpm e 122 &#177; 24 bpm, respectivamente) mostra um valor do coeficiente de correla&#231;&#227;o moderado, mas significante (r = 0,66; p = 0,005, <xref ref-type="fig" rid="aop04811fig02">figura 2A</xref>). A rela&#231;&#227;o do VO<sub>2</sub>pico estimado no TC6'2, atrav&#233;s de f&#243;rmula consagrada na literatura<sup>10</sup> e no TCP, atrav&#233;s da an&#225;lise direta dos gases expirados, (20,49 &#177; 1,99 ml/kg/min para TC6'2 e 14,12 &#177; 4,11 ml/kg/min para TCP), mostra valor moderado de correla&#231;&#227;o, mas ainda significante (r = 0,57; p = 0,02, <xref ref-type="fig" rid="aop04811fig02">figura 2B</xref>). Por fim, a an&#225;lise da rela&#231;&#227;o entre a DP no TC6'2 e o VO<sub>2</sub>pico obtido no TCP (550,31 &#177; 66,40 m e 1025,25 &#177; 332,13 ml/min) mostra valor moderado e significante do coeficiente de correla&#231;&#227;o (r = 0,70; p = 0,002, <xref ref-type="fig" rid="aop04811fig02">figura 2C</xref>).</p>
    <p><fig id="aop04811fig02"/>&#13;
&#160;&#13;
&#160;&#13;
</p>
    <p>
      <fig id="aop04811fig02ab">
        <graphic xlink:href="1678-4170-abc-97-01-0059-00056-gf03.jpg"/></fig>
    </p>
    <p>&#13;
  <fig id="aop04811fig02xc"/><fig id="aop04811fig02c"><graphic xlink:href="1678-4170-abc-97-01-0059-00056-gf04.jpg"/></fig></p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A avalia&#231;&#227;o da capacidade subm&#225;xima de esfor&#231;o atrav&#233;s do TC6' vem sendo incorporada &#224; pr&#225;tica cl&#237;nica para pacientes com IC em raz&#227;o de f&#225;cil aplica&#231;&#227;o, baixo custo e seguran&#231;a. Esse teste tem se mostrado &#250;til e confi&#225;vel na avalia&#231;&#227;o da capacidade funcional, progn&#243;stico e efic&#225;cia terap&#234;utica de pacientes com essa s&#237;ndrome<sup>5,8,9,15</sup>.</p>
    <p>Um dos objetivos deste estudo foi analisar a reprodutibilidade da aplica&#231;&#227;o do TC6' na IC, mediante a realiza&#231;&#227;o de dois testes sequenciais para o mesmo paciente. Quanto a esse aspecto, os nossos dados mostram que a an&#225;lise das vari&#225;veis DP, FC, VO<sub>2</sub> e percep&#231;&#227;o de esfor&#231;o medidas nos dois testes de caminhada de seis minutos tiveram forte correla&#231;&#227;o, evidenciando sua reprodutibilidade. Como consenso, a maioria dos trabalhos encontrados na literatura tem utilizado a aplica&#231;&#227;o de mais de um teste para determinar a dist&#226;ncia percorrida, j&#225; que esse procedimento pode melhorar a familiariza&#231;&#227;o da t&#233;cnica pelo paciente<sup>5,8,12</sup>. Corroborando os nossos achados, Cahalin e cols.<sup>10</sup> testaram a reprodutibilidade do TC6' em 20 pacientes, e encontraram um valor do coeficiente de correla&#231;&#227;o intraclasse estimado de 0,96.</p>
    <p>O teste de esfor&#231;o cardiopulmonar tem sido amplamente usado na mensura&#231;&#227;o objetiva do VO<sub>2</sub>, e &#233; atualmente considerado o padr&#227;o de refer&#234;ncia na avalia&#231;&#227;o da capacidade funcional<sup>16,17</sup>. Ele tem sido muito utilizado como prognosticador de morbimortalidade em pacientes com IC, como demonstrou Gitt e cols.<sup>18</sup> em um estudo com 223 pacientes portadores de IC em que evidenciaram que o grupo de pacientes com VO<sub>2</sub>pico <underline>&lt;</underline> 14 ml/kg/min, ou VO<sub>2</sub> no limiar de anaerobiose &lt; 11 ml/kg/min apresentava maior risco de morte. Por&#233;m, essa t&#233;cnica apresenta alto custo, requer equipamento sofisticado, m&#227;o de obra especializada e somente &#233; encontrada em determinados centros<sup>5</sup>; al&#233;m disso, necessita uma maior colabora&#231;&#227;o do paciente.</p>
    <p>Na presente amostra estudada, a m&#233;dia do VO<sub>2</sub>pico obtida pela medida direta no TCP foi de 14,12 &#177; 4,11 ml/kg/min. Quando essa m&#233;dia foi correlacionada com a m&#233;dia obtida atrav&#233;s da medida indireta no TC6' (20,49 &#177; 1,99 ml/kg/min), observamos que, apesar de a f&#243;rmula utilizada para o c&#225;lculo do VO<sub>2</sub> no TC6' superestimar o valor real da medida do VO<sub>2</sub>pico, houve uma correla&#231;&#227;o moderada entre elas. Usando a mesma f&#243;rmula, Cahalin e cols.<sup>10</sup> tamb&#233;m mostraram em pacientes com IC uma correla&#231;&#227;o linear entre o VO<sub>2</sub>pico no TC6' e no TCP.</p>
    <p>Uma vari&#225;vel de grande import&#226;ncia na avalia&#231;&#227;o progn&#243;stica do TC6' em pacientes com IC &#233; a m&#225;xima DP. Alguns estudos t&#234;m mostrado que um valor menor ou igual a 300 metros em seis minutos indica pior progn&#243;stico, em compara&#231;&#227;o com os pacientes que percorrem mais que 300 metros<sup>10,19</sup>. Nosso trabalho foi capaz de demonstrar que duas vari&#225;veis cr&#237;ticas, a DP no TC6' e o VO<sub>2</sub>pico no TCP, apresentam uma correla&#231;&#227;o em n&#237;vel moderado e estatisticamente significante, no pico do esfor&#231;o em pacientes com IC classe funcional I - II (r = 0,70; p = 0,002). Estudos pr&#233;vios<sup>10,17</sup> confirmam nossos resultados mostrando boa correla&#231;&#227;o entre os resultados do TC6' e do TCP<sup>12,20,21</sup>. Faggiano e cols.<sup>20</sup>, em uma amostra de 26 pacientes com IC (NYHA II - IV), encontraram uma significante correla&#231;&#227;o entre a DP no TC6' e o VO<sub>2</sub>pico atingido no TCP (r = 0,63).</p>
    <p>Os resultados relatados na literatura, contudo, n&#227;o s&#227;o homog&#234;neos. No estudo de Lucas e cols.<sup>12</sup>, conduzido com 307 pacientes com IC avan&#231;ada (fra&#231;&#227;o de eje&#231;&#227;o &lt; 35%), o VO<sub>2</sub>pico obtido no TCP sintoma limitado, aplicado num subgrupo de 213 pacientes com VO<sub>2</sub>pico entre 10 - 20 ml/kg/min, exibiu uma baixa correla&#231;&#227;o com a DP no TC6' (r = 0,28). Em outro estudo, Roul e cols.<sup>19</sup>, tamb&#233;m conduzido em 121 pacientes com IC (classes funcionais NYHA- II - III, fra&#231;&#227;o de eje&#231;&#227;o 29,6% &#177; 13%), demonstraram baixa correla&#231;&#227;o entre VO<sub>2</sub>pico no TCP sintoma limitado e DP no TC6' (r = 0,24).</p>
    <p>O principal fator respons&#225;vel pela aparente discord&#226;ncia entre os nossos resultados e os de outros investigadores, em contraposi&#231;&#227;o com os resultados obtidos nos estudos citados acima, pode residir nas caracter&#237;sticas da popula&#231;&#227;o estudada em cada estudo, particularmente a gravidade da IC. Dessa forma, &#233; plaus&#237;vel supor que, nas popula&#231;&#245;es com IC avan&#231;ada (CF III-IV), a correla&#231;&#227;o entre TCP e TC6' seja menor. Refor&#231;ando essa hip&#243;tese, no estudo de Lucas e cols.<sup>12</sup>, a aplica&#231;&#227;o da an&#225;lise de correla&#231;&#227;o n&#227;o restrita aos pacientes mais graves resultou em melhores n&#237;veis de correla&#231;&#227;o (r = 0,52).</p>
    <p>A ocorr&#234;ncia do comportamento linear entre as respostas da FC e o do VO<sub>2</sub><sup>21</sup> durante exerc&#237;cio f&#237;sico din&#226;mico tem fornecido embasamento para a aplica&#231;&#227;o de m&#233;todos indiretos de avalia&#231;&#227;o da reserva funcional para a prescri&#231;&#227;o de exerc&#237;cio f&#237;sico e o seu uso em testes de esfor&#231;o que n&#227;o disp&#245;em da medida direta do consumo de oxig&#234;nio. Comparando a FC pico atingida nos TCP e TC6', pudemos observar uma moderada, mas significante, correla&#231;&#227;o (r = 0,66; p = 0,005). Considerando-se que a resposta cronotr&#243;pica foi semelhante nos dois testes, esse achado ganha relev&#226;ncia, visto que o TC6' &#233; um m&#233;todo de avalia&#231;&#227;o bastante simples e acess&#237;vel. Ressalte-se que, de acordo com I Consenso Nacional de Reabilita&#231;&#227;o Cardiovascular<sup>22</sup>, para que a prescri&#231;&#227;o de atividade f&#237;sica seja realizada de forma segura e adequada, a melhor maneira seria pelo emprego da FC pico, obtida em um teste de esfor&#231;o, limitado por sintoma.</p>
    <p>Acreditamos que a partir dos presentes resultados a prescri&#231;&#227;o do exerc&#237;cio f&#237;sico pela utiliza&#231;&#227;o do TC6' pode ser uma op&#231;&#227;o segura, eficaz e de baixo custo em pacientes com IC menos grave, em classe funcional I-II.</p>
    <p>Em uma recente publica&#231;&#227;o, Guazzi e cols.<sup>23</sup> estudaram 253 pacientes com diagn&#243;stico de IC, objetivando a compara&#231;&#227;o cl&#237;nica e progn&#243;stica entre os testes cardiopulmonar e de caminhada de seis minutos. Os autores confirmaram ser o TC6' uma ferramenta confi&#225;vel e simples para quantifica&#231;&#227;o da intoler&#226;ncia ao esfor&#231;o em pacientes com IC, por&#233;m, consideram que mais evid&#234;ncias s&#227;o necess&#225;rias para recomendar a utiliza&#231;&#227;o do TC6' como marcador progn&#243;stico alternativo isolado ou associado a outras vari&#225;veis derivadas do TCP.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Nossos resultados nos levam a concluir que, quando aplicado aos pacientes com IC em classe funcional n&#227;o avan&#231;ada (CF NYHA I-II), o TC6' &#233; um m&#233;todo de elevada reprodutibilidade, e que exibe boa correla&#231;&#227;o com as vari&#225;veis medidas no teste cardiopulmonar.</p>
    <p>Dessa forma, nossos resultados sugerem que o TC6'constitui-se numa alternativa adequada, segura e de baixo custo para a prescri&#231;&#227;o de exerc&#237;cios f&#237;sicos aer&#243;bicos em pacientes com IC em classe funcional n&#227;o avan&#231;ada.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo foi financiado pela FAEPA, CAPES, CNPq e FAPESP.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="ad" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p>Eduardo Elias Vieira de Carvalho </p>
        <p> Rua Appa, 1484 - Monte Alegre </p>
        <p> 14051-060 - Ribeir&#227;o Preto, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="carvalhoeev@usp.br">carvalhoeev@usp.br</email>, </p>
        <p>
          <email xlink:href="carvalhoeev@hotmail.com">carvalhoeev@hotmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 21/07/10; revisado recebido em 01/12/10; aceito em 11/01/11.</p>
    <p>
      <italic>Full texts in English - </italic>
      <ext-link ext-link-type="uri" xlink:href="http://www.arquivosonline.com.br">http://www.arquivosonline.com.br</ext-link>
    </p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Barbosa Filho J, Moura RS, Barbosa PR. Insufici&#234;ncia card&#237;aca. S&#227;o Paulo: Fundo Editorial BYK; 1994. p. 11.</mixed-citation>
        <element-citation publication-type="book">
          <source>Insufici&#234;ncia card&#237;aca</source>
          <date>
            <year>1994</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Barbosa Filho</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moura</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Barbosa</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Mann DL. Pathophysiology of heart failure. In: Libby P, Bonow RO, Mann DL, Zipes DP. Braunwald's heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelphia: Saunders; 2007. p. 9901-9</mixed-citation>
        <element-citation publication-type="book">
          <source>Braunwald's heart disease: a textbook of cardiovascular medicine</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>9901</fpage>
          <lpage>9</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Mann</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Zipes</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Bocchi EA, Marandes-Braga FG, Ayub-Ferreira SM, Rohde LE, Oliveira WA, Almeida DE / Sociedade Brasileira de Cardiologia. III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica. Arq Bras Cardiol. 2009;93(1 supl. 1):1-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1</fpage>
          <lpage>71</lpage>
          <issue>1</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Marandes-Braga</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Ayub-Ferreira</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Rohde</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998;98(24):2709-15.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>2709</fpage>
          <lpage>15</lpage>
          <issue>24</issue>
          <volume>98</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hambrecht</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fiehn</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Weigl</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gielen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hamann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kaiser</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Zugck C, Kruger C, Durr S, Gerber SH, Haunstetter A, Hornig K, et al. Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J. 2000;21(7):540-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>540</fpage>
          <lpage>9</lpage>
          <issue>7</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zugck</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kruger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Durr</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gerber</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Haunstetter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hornig</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132(8):919-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure</article-title>
          <source>Can Med Assoc J</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>919</fpage>
          <lpage>23</lpage>
          <issue>8</issue>
          <volume>132</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guyatt</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Fallen</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Pugsley</surname>
              <given-names>SO</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Lipkin DP, Scriven AJ, Crake T, Poole-Wilson PA. Six minute walking test for assessing exercise capacity in chronic heart failure. Br Med J (Clin Res Ed). 1986;292(6521):653-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Six minute walking test for assessing exercise capacity in chronic heart failure</article-title>
          <source>Br Med J (Clin Res Ed)</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>653</fpage>
          <lpage>5</lpage>
          <issue>6521</issue>
          <volume>292</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lipkin</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Scriven</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Crake</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Poole-Wilson</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Opasich C, Pinna GD, Mazza A, Febo O, Ricardi R, Ricardi PG, et al. Six-minute walking performance in patients with moderate-to-severe heart failure: is it a useful indicator in clinical practice? Eur Heart J. 2001;22(6):488-96.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Six-minute walking performance in patients with moderate-to-severe heart failure: is it a useful indicator in clinical practice?</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>488</fpage>
          <lpage>96</lpage>
          <issue>6</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Opasich</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pinna</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Mazza</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Febo</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ricardi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ricardi</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. For the SOLVD Investigartors. JAMA. 1993;270(14):1702-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction: For the SOLVD Investigartors</article-title>
          <source>JAMA</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>1702</fpage>
          <lpage>7</lpage>
          <issue>14</issue>
          <volume>270</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bittner</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Weiner</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>McIntyre</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Bangdiwala</surname>
              <given-names>SI</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Cahalin LP, Mathier MA, Semigran MJ, Dec GW, DiSalvo TG. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest. 1996;110(2):325-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure</article-title>
          <source>Chest</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>325</fpage>
          <lpage>32</lpage>
          <issue>2</issue>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cahalin</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Mathier</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Semigran</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Dec</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>DiSalvo</surname>
              <given-names>TG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11.  Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Carboxymaltose in patients with heart failure and iron deficiency</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>2436</fpage>
          <lpage>48</lpage>
          <issue>25</issue>
          <volume>361</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Colet</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Filippatos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Willenheimer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dickstein</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Drexler</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Lucas C, Stevenson LW, Johnson W, Hartley H, Hamilton MA, Walden J, et al. The 6-minute walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival. Am Heart J. 1999;138(4 Pt 1):618-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The 6-minute walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>618</fpage>
          <lpage>24</lpage>
          <issue>4 Pt 1</issue>
          <volume>138</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lucas</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hartley</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Walden</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. ATS Statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ATS Statement: guidelines for the six-minute walk test</article-title>
          <source>Am J Respir Crit Care Med</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>111</fpage>
          <lpage>7</lpage>
          <issue>1</issue>
          <volume>166</volume>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Wasserman K, Hansen JE, Sue D, Whipp BJ, Casaburi R. Principles of exercise testing and interpretation. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2004.</mixed-citation>
        <element-citation publication-type="book">
          <source>Principles of exercise testing and interpretation</source>
          <date>
            <year>2004</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Wasserman</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Sue</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Whipp</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Casaburi</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Rubim VSM, Drumond Neto C, Romeo JLM, Montera MW. Prognostic value of the six-minute walk test in heart failure. Arq Bras Cardiol. 2006;86(2):120-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of the six-minute walk test in heart failure</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>120</fpage>
          <lpage>5</lpage>
          <issue>2</issue>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rubim</surname>
              <given-names>VSM</given-names>
            </name>
            <name>
              <surname>Drumond Neto</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Romeo</surname>
              <given-names>JLM</given-names>
            </name>
            <name>
              <surname>Montera</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83(3):778-86.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>778</fpage>
          <lpage>86</lpage>
          <issue>3</issue>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mancini</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Eisen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kussmaul</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mull</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Edmunds Jr</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Riley M, McFarland J, Stanford CF, Nicholls DP. Oxygen consumption during corridor walk testing in chronic heart failure. Eur Heart J. 1992;13(6):789-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Oxygen consumption during corridor walk testing in chronic heart failure</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>789</fpage>
          <lpage>93</lpage>
          <issue>6</issue>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Riley</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McFarland</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stanford</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Nicholls</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Gitt AK, Wasserman K, Kilkowski C, Kleemann T, Kilkowski A, Bangert M, et al. Exercise anaerobic threshould and ventilatory efficiency identify heart failure patients for high risk of early death. Circulation. 2002;106(24):3079-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise anaerobic threshould and ventilatory efficiency identify heart failure patients for high risk of early death</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>3079</fpage>
          <lpage>84</lpage>
          <issue>24</issue>
          <volume>106</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gitt</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Wasserman</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kilkowski</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kleemann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kilkowski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bangert</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Roul G, Germain P, Bareiss P. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure. Am Heart J. 1998;136(3):449-57.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>449</fpage>
          <lpage>57</lpage>
          <issue>3</issue>
          <volume>136</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Roul</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Germain</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bareiss</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Faggiano P, D'aloia A, Gualeni A, Lavatelli A, Giordano A. Assesment of oxygen uptake during the six minute walk test in patients with heart failure: preliminary experience with a portable device. Am Heart J. 1997;134(2 Pt 1):203-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assesment of oxygen uptake during the six minute walk test in patients with heart failure: preliminary experience with a portable device</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>203</fpage>
          <lpage>6</lpage>
          <issue>2 Pt 1</issue>
          <volume>134</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Faggiano</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>D'aloia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gualeni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lavatelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giordano</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Lange A K, Shephard R, Denolin H, Varnasukas E, Masironi R. Fundamentals of exercise testing. Gen&#233;ve: WHO; 1971.</mixed-citation>
        <element-citation publication-type="book">
          <source>Fundamentals of exercise testing</source>
          <date>
            <year>1971</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Lange A</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shephard</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Denolin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Varnasukas</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Masironi</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Godoy M, Bellini AJ, Passaro JC, Mastrocolla LE / Departamento de Ergometria e Reabilita&#231;&#227;o Cardiovascular / Sociedade Brasileira de Cardiologia. I Consenso nacional de reabilita&#231;&#227;o cardiovascular. Arq Bras Cardiol. 1997;69(4):267-91.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>I Consenso nacional de reabilita&#231;&#227;o cardiovascular</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>267</fpage>
          <lpage>91</lpage>
          <issue>4</issue>
          <volume>69</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Godoy</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bellini</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Passaro</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Mastrocolla</surname>
              <given-names>LE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Guazzi M, Dickstein K, Vicenzi M, Arena R. Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights. Circ Heart Fail. 2009;2(6):549-55.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights</article-title>
          <source>Circ Heart Fail</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>549</fpage>
          <lpage>55</lpage>
          <issue>6</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guazzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dickstein</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vicenzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arena</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Heart failure: comparison between six-minute walk test and cardiopulmonary test</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Chronic heart failure (HF) is a syndrome characterized by reduced cardiac output in relation to the metabolic needs of the organism, as well as metabolic and neurohormonal axis abnormalities. Symptoms such as fatigue and dyspnoea are notorious and stress tests are widely used to assess functional capacity, prognosis and effectiveness of therapeutic interventions in this syndrome. OBJECTIVE: To evaluate the reproducibility of the six-minute walk test (6MW) in patients with HF and correlate the magnitude of the variables reached at peak exercise of the 6MWT with a cardiopulmonary exercise test (CPET). METHODS: We studied 16 patients (12 men and 4 women) diagnosed with HF FC I-II (NYHA). The volunteers underwent two 6MWT (6MWT'1 and 6MWT'2) with 30-minute interval between them; then, they underwent a maximum CPET. RESULTS: All variables obtained in the two 6MWT' proved to be significant with high correlations: distance walked (DW) (r = 0.93, p &lt; 0.0001), heart rate (HR) (r = 0.89, p &lt; 0.0001), oxygen consumption (VO2) (r = 0.93, p &lt; 0.0001) and scale of perceived exertion (r = 0.85, p &lt; 0.0001). In turn, all variables analyzed in the 6MWT' showed significant and moderate correlations with the variables obtained from the CPET, namely: peak HR (r = 0.66; p = 0.005); VO2 (r = 0.57; p = 0.02) and VO2 in the CPET and DT in the 6MWT'2 (r = 0.70; p = 0.002). CONCLUSION: The 6MWT was reproducible in this group of patients with HF (NYHA - I-II) and correlated with the CPET. Therefore, it is a tool for reliable evaluation, and a suitable, safe and low-cost alternative for the prescription of aerobic exercise in patients with HF.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Heart failure</kwd>
        <kwd>exercise</kwd>
        <kwd>walking</kwd>
        <kwd>respiratory function tests</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <fn id="add-body2">
          <label>
            <bold>Heart failure: comparison between six-minute walk test and cardiopulmonary test</bold>
          </label>
          <p>
            <bold>Eduardo Elias Vieira de Carvalho<sup>I</sup>; Daniela Caetano Costa<sup>I</sup>; J&#250;lio C&#233;sar Cresc&#234;ncio<sup>I</sup>; Giovani Luiz De Santi<sup>I</sup>; Val&#233;ria Papa<sup>I</sup>; Fabiana Marques<sup>I</sup>; Andr&#233; Schmidt<sup>II</sup>; Jos&#233; Antonio Marin-Neto<sup>II</sup>; Marcus Vin&#237;cius Sim&#245;es<sup>II</sup>; Louren&#231;o Gallo Junior<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Laborat&#243;rio de Fisiologia do Exerc&#237;cio - Departamento de Cl&#237;nica M&#233;dica - Divis&#227;o de Cardiologia - Faculdade de Medicina de Ribeir&#227;o Preto - USP</p>
      <p><sup>II</sup>Departamento de Cl&#237;nica M&#233;dica - Divis&#227;o de Cardiologia - Faculdade de Medicina de Ribeir&#227;o Preto - USP, Ribeir&#227;o Preto, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Chronic heart failure (HF) is a syndrome characterized by reduced cardiac output in relation to the metabolic needs of the organism, as well as metabolic and neurohormonal axis abnormalities. Symptoms such as fatigue and dyspnoea are notorious and stress tests are widely used to assess functional capacity, prognosis and effectiveness of therapeutic interventions in this syndrome.</p>
      <p><bold>OBJECTIVE:</bold> To evaluate the reproducibility of the six-minute walk test (6MW) in patients with HF and correlate the magnitude of the variables reached at peak exercise of the 6MWT with a cardiopulmonary exercise test (CPET).</p>
      <p><bold>METHODS:</bold> We studied 16 patients (12 men and 4 women) diagnosed with HF FC I-II (NYHA). The volunteers underwent two 6MWT (6MWT'1 and 6MWT'2) with 30-minute interval between them; then, they underwent a maximum CPET.</p>
      <p><bold>RESULTS:</bold> All variables obtained in the two 6MWT' proved to be significant with high correlations: distance walked (DW) (r = 0.93, p &lt; 0.0001), heart rate (HR) (r = 0.89, p &lt; 0.0001), oxygen consumption (VO<sub>2</sub>) (r = 0.93, p &lt; 0.0001) and scale of perceived exertion (r = 0.85, p &lt; 0.0001). In turn, all variables analyzed in the 6MWT' showed significant and moderate correlations with the variables obtained from the CPET, namely: peak HR (r = 0.66; p = 0.005); VO<sub>2</sub> (r = 0.57; p = 0.02) and VO<sub>2</sub> in the CPET and DT in the 6MWT'2 (r = 0.70; p = 0.002).</p>
      <p><bold>CONCLUSION:</bold> The 6MWT was reproducible in this group of patients with HF (NYHA - I-II) and correlated with the CPET. Therefore, it is a tool for reliable evaluation, and a suitable, safe and low-cost alternative for the prescription of aerobic exercise in patients with HF.</p>
      <p><bold>Keywords:</bold> Heart failure; exercise; walking; respiratory function tests.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Chronic heart failure (HF) is the final common pathway of most heart diseases. It is a complex clinical syndrome characterized by the inability of the heart to generate cardiac output at levels capable of meeting the metabolic needs of the organism<sup>1</sup> associated with metabolic and inflammatory disorders and neurohormonal activation<sup>2</sup>. It is a major public health problem, considering the increasing prevalence and hospitalization rates associated with high morbidity and mortality. Scientific and technological progress and better socioeconomic conditions have led to increased longevity of the general population and also of patients with heart disease, a factor associated with the sharp rise in the incidence of HF in Brazil and in the world<sup>3</sup>.</p>
      <p>Patients with HF usually have exacerbation of symptoms during exercise and exercise tolerance measure is used to assess functional capacity, which correlates with cardiac failure severity. Thus, the use of stress testing for objective measurement of functional capacity is a valuable tool for stratifying the prognosis of patients with heart failure<sup>4,5</sup>. In this context, the cardiopulmonary exercise testing (CPET) has been established as the reference standard.</p>
      <p>The six-minute walk test (6MW), due to its wide availability, security and ease of implementation, is being used increasingly as an alternative to CPET to evaluate the functional capacity of patients with HF<sup>5-8</sup>. It is considered a submaximal exercise that mimics everyday activities and is generally well tolerated by patients. It should be noted that the distance walked during the 6MWT is an independent predictor of mortality and hospitalizations in patients with HF<sup>3,9,10</sup>. Additionally, increasing the distance walked in six minutes has been shown to be a sensitive index to assess response to therapeutic interventions in HF<sup>11</sup>.</p>
      <p>Despite its widespread use, there is still controversy whether the results obtained in the 6MWT' show a proper correlation with those derived from the CPET, in patients with different HF severity levels<sup>12</sup>. Therefore, the objective of this study was to evaluate the reproducibility of the 6MWT' and compare the results of functional capacity evaluation indices obtained in the 6MWT' with CPET, in patients with chronic heart failure not advanced.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>The patients included in this study were selected from the sample of a project previously conducted in our Institution, whose main objective was to assess the contractile reserve in patients with heart failure of nonischemic etiology. That original study prospectively investigated 30 patients with HF functional class I - III (NYHA). The patients were clinically stable, using medication properly optimized and followed up in the outpatient HF clinic of our institution. Among these patients, we identified those whose existing CPET and 6MWT data could be recovered from the relevant processing and analysis systems. Thus, we identified 16 patients (12 men and 4 women) with mean age (&#177; SD) 57.5 (&#177; 10.1) years, diagnosed with HF functional class I-II (NYHA). All of them had participated voluntarily in the study, whose main anthropometric, clinical and laboratory characteristics are summarized in <xref ref-type="table" rid="tab1-body2">Table 1</xref>.</p>
      <table-wrap id="tab1-body2">
        <graphic xlink:href="1678-4170-abc-97-01-0059-00056-gt01-en.jpg"/></table-wrap>
      <p>At the time of testing, all of them signed an informed consent and the study was approved by the Research Ethics Committee of HCFMRP - USP.</p>
      <p>Walk test and cardiopulmonary exercise test</p>
      <p>After a careful clinical evaluation and inclusion in the study, patients undergone the 6MWT', and within a week, were submitted to CPET. This narrow time window aims to limit the potential influence of changes in the clinical status and severity of symptoms on the results of functional capacity tests. All tests were performed in the morning to standardize the influence of circadian variations in heart rate (HR) and other cardiorespiratory variables.</p>
      <p>The 6MWT' were applied by the same investigators in a corridor of 30 meters, with markings every 5 meters for accurately determining the distance walked<sup>13</sup>. Patients were monitored by Polar<sup>TM</sup> S810 frequency meter, with instantaneous recording and storage of HR values; the blood pressure values were obtained by auscultation (aneroid sphygmomanometer) before the test, immediately after the end, in the second and fourth minutes of recovery, and the index of perception of Borg exercise intensity (CR10) was obtained at the beginning and at the end of the test. Peak HR was obtained on further analysis of the data stored by the software POLAR<sup>TM</sup> Precision Performance SW.</p>
      <p>Patients were instructed to walk at a maximum speed during six minutes (6MWT'1); if necessary, they could stop to rest and then resume the test. The observers used stimulation sentences for patients to maintain the same walking pace through the end of the test, and after six minutes, the distance walked (DW) was measured. After an interval of 30 minutes and a maximum of 45 minutes, the patients repeated the walk test (6MWT'2), following the same method.</p>
      <p>The calculation of estimated oxygen consumption (VO<sub>2</sub>) for the walk test was performed using a formula previously published<sup>10</sup>.</p>
      <p>All volunteers were submitted to a maximal exercise test. The protocol consisted of dynamic physical exercise in a seated position on an electronically-braked cycle ergometer (Corival 400, Quinton). The power applied in the cycle ergometer was ramp type with intensity determined by the formula developed by Wasserman et al<sup>14</sup> based on anthropometric characteristics, age and gender. Patients were encouraged to make the effort applied to the power at which they reached cardiorespiratory exhaustion. In all patients studied, the onset of the ramp was preceded by an effort at minimum load (3-4 Watts) at a constant speed of 60 revolutions per minute, with the aim of obtaining a preheating of the physiological systems involved in carrying the oxygen. The ventilatory variables were obtained in this protocol using an ergospirometer (CPX/D MedGraphics), which allows the acquisition, processing and storage of data from breath to breath. Peak VO<sub>2</sub> and HR values were expressed as an average over the last 30 seconds of record, and were chosen to be compared with the distance walked and the VO<sub>2</sub> inferred in the 6MWT'.</p>
      <p>To analyze the correlation between the 6MWT' and CPET, we chose to use the 6MWT'2, since, in the second test, it is expected that patients are better acquainted with the methodology and can perform it with greater control over the technique.</p>
      <p>Statistical analysis</p>
      <p>Data were expressed as mean &#177; standard deviation. The statistical analysis was performed using Spearman's nonparametric correlation test. The level of statistical significance was 5%.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>Correlation data between 6MWT'1 and 6MWT'2 are shown in <xref ref-type="fig" rid="en_aop04811fig01-body2">Figure 1</xref>. The DW showed a high correlation coefficient, statistically significant between 6MWT'1 and 6MWT'2 (545.47 &#177; 74.49 m and 550.31 &#177; 66.40 m, respectively) (r = 0.93; p &lt; 0.0001, Figure 1A). Peak HR response was measured by the cardiofrequencymeter at the end of the sixth minute of each test (128 &#177; 24 bpm for 6MWT'1 and 129 &#177; 25 bpm for 6MWT'2) also showed significant correlation (r = 0.89; p &lt; 0.0001, <xref ref-type="fig" rid="en_aop04811fig01-body2">figure 1B</xref>). Similarly, peak VO<sub>2</sub> estimated in 6MWT'1 and 6MWT'2 (20.34 &#177; 2.23 ml/kg/min; 20.49 &#177; 1.99 ml/kg/min, respectively) showed high and significant correlation value (r = 0.93, p &lt; 0.0001, <xref ref-type="fig" rid="en_aop04811fig01-body2">figure 1C</xref>). Finally, the intensity of perceived exertion at the end of each test (4.5 &#177; 1.7 and 4.8 &#177; 1.7 for 6MWT'1 and 6MWT'2, respectively), as assessed by the Borg scale, also showed a highly significant correlation (r = 0.85, p &lt; 0.0001, <xref ref-type="fig" rid="en_aop04811fig01-body2">figure 1D</xref>).</p>
      <p content-type="html"><fig id="en_aop04811fig01-body2"><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/5x4NjhJCQ9fZpKDMQSpb7Ms/e5ea2833abf1d77ae0dd8eed10b685beec68f470.jpg"/><graphic xlink:href="1678-4170-abc-97-01-0059-00056-gf01-en.jpg"/></fig>&#13;
&#160;&#13;
&#160;&#13;
</p>
      <p><xref ref-type="fig" rid="en_aop04811fig02-body2">Figure 2</xref> illustrates the correlated parameters between 6MWT'2 and CPET. The ratio of peak HR in the 6MWT'2 and CPET (129 &#177; 25 bpm and 122 &#177; 24 bpm, respectively) shows a moderate but significant correlation coefficient (r = 0.66, p = 0.005, <xref ref-type="fig" rid="en_aop04811fig02-body2">figure 2A</xref>). The ratio of estimated VO<sub>2</sub> peak in 6MWT'2 through a formula set forth in the literature<sup>10</sup> and in the CPET, through direct analysis of expired gases (20.49 &#177; 1.99 ml/kg/min for 6MWT'2 and 14.12 &#177; 4.11 ml/kg/min for CPET), shows a moderate correlation value, but still significant (r = 0.57; p = 0.02, <xref ref-type="fig" rid="en_aop04811fig02-body2">figure 2B</xref>). Finally, the analysis of the relationship between DW in the 6MWT'2 and the peak VO<sub>2</sub> obtained in the CPET (550.31 &#177; 66.40 and 1025.25 &#177; 332.13 ml/min) shows a moderate and significant correlation coefficient (r = 0.70; p = 0.002, <xref ref-type="fig" rid="en_aop04811fig02-body2">figure 2C</xref>).</p>
      <p content-type="html"><fig id="en_aop04811fig02-body2"><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/5x4NjhJCQ9fZpKDMQSpb7Ms/2d01c7c6f002130891ff601d91caaa9619966def.jpg"/><graphic xlink:href="1678-4170-abc-97-01-0059-00056-gf02-en.jpg"/></fig>&#13;
&#160;&#13;
&#160;&#13;
</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>Assessment of submaximal effort through the 6MWT' has been incorporated into clinical practice for patients with HF due to easy application, low cost and safety. This test has proven useful and reliable in the assessment of functional capacity, prognosis and therapeutic effectiveness in patients with this syndrome<sup>5,8,9,15</sup>.</p>
      <p>One objective of this study was to analyze the reproducibility of the application of the 6MWT' in HF, by conducting two sequential tests for the same patient. In this respect, our data show that the analysis of the variables DW, HR, VO<sub>2</sub>, and perceived exertion measured in the two six-minute walk tests had a strong correlation, showing its reproducibility. As a consensus, most studies found in the literature have used the application of more than one test to determine the distance walked, since this procedure can improve patients' familiarity with the technique<sup>5,8,12</sup>. Corroborating our findings, Cahalin et al<sup>10</sup> tested the reproducibility of the 6MWT' in 20 patients, and found an estimated intraclass correlation coefficient of 0.96.</p>
      <p>The cardiopulmonary stress test has been widely used in the objective measurement of the VO<sub>2</sub>, and is currently considered the reference standard in assessing the functional capacity funcional<sup>16,17</sup>. It has long been used as a predictor of morbidity and mortality in HF patients, as demonstrated by Gitt et al<sup>18</sup> in a study involving 223 patients with HR that showed that the group of patients with peak VO<sub>2</sub><underline>&lt;</underline> 14 ml/kg/min or VO<sub>2</sub> at anaerobic threshold &lt; 11 ml/kg/min had a greater risk of death. However, this technique has a high cost, requires sophisticated equipment, skilled labor and is only found in certain centers<sup>5</sup>; besides, it requires greater patient cooperation.</p>
      <p>In this sample, average peak VO<sub>2</sub> obtained by direct measurement in CPET was 14.12 &#177; 4.11 ml/kg/min. When this average was correlated with the average obtained by indirect measurement the in 6MWT' (20.49 &#177; 1.99 ml/kg/min), we observed that although the formula used to calculate the VO<sub>2</sub> in the 6MWT overestimates the actual peak VO<sub>2</sub>, there was a moderate correlation between them. Using the same formula, Cahalin et al<sup>10</sup> also demonstrated in patients with HF a linear correlation between peak VO<sub>2</sub> in 6MWT and CPET.</p>
      <p>A variable of great importance in the prognostic evaluation of 6MWT in patients with HF is the maximum DW. Some studies have shown that a value smaller than or equal to 300 meters in six minutes indicates a worse prognosis compared with patients walking more than 300 meters<sup>10,19</sup>. Our study was able to show that two critical variables, the DW in 6MWT' and peak VO<sub>2</sub> in the CPET have a correlation at a moderate level and statistically significant at peak exertion in patients with HF functional class I - II (r = 0.70; p = 0.002). Previous studies<sup>10,17</sup> confirm our results showing a good correlation between the results of the 6MWT' and CPET<sup>12,20,21</sup>. Faggiano et al<sup>20</sup> in a sample of 26 patients with HF (NYHA II - IV), found a significant correlation between the DW in the 6MWT' and peak VO<sub>2</sub> reached in the CPET (r = 0.63).</p>
      <p>The results reported in the literature, however, are not homogeneous. In the study by Lucas et al<sup>12</sup> conducted with 307 patients with advanced HF (ejection fraction &lt; 35%), peak VO<sub>2</sub> reached in symptom-limited CPET, applied in a subgroup of 213 patients with a peak VO<sub>2</sub> between 10 to 20 ml/kg/min showed a low correlation with the DW in the 6MWT' (r = 0.28). In another study, Roul et al<sup>19</sup>, also conducted in 121 patients with HF (functional classes NYHA-II-III, ejection fraction 29.6% &#177; 13%) demonstrated a low correlation between the peak VO<sub>2</sub> in symptom-limited CEPT, and DW in the 6MWT' (r = 0.24).</p>
      <p>The main factor responsible for the apparent discrepancy between our results and those of other researchers, in contrast to the results obtained in the studies cited above, may lie in the characteristics of the population in each study, particularly the severity of HF. Thus, it is plausible that, in populations with advanced HF (FC III-IV), the correlation between CPET and 6MWT' is smaller. Reinforcing this hypothesis, in the study by Lucas et al<sup>12</sup>, the application of correlation analysis not restricted to the most severely ill patients resulted in better levels of correlation (r = 0.52).</p>
      <p>The occurrence of the linear relationship between HR responses and VO<sub>221</sub> during dynamic exercise has provided the basis for application of indirect methods for assessing functional reserve for exercise prescription and its use in stress tests that do not have direct measurement of oxygen consumption. Comparing the peak HR achieved in the CPET and 6MWT', we observed a moderate but significant correlation (r = 0.66, p = 0.005). Considering that the chronotropic response was similar in both tests, this finding becomes relevant, since the 6MWT' is a very simple and accessible evaluation method. It is noteworthy that, according to the 1<sup>st</sup> National Cardiovascular Rehabilitation Consensus<sup>22</sup>, so that the prescription of physical activity is performed safely and appropriately, the best way would be using peak HR obtained in a symptom-limited stress test.</p>
      <p>We believe that from the present results, the prescription of exercise by use of 6MWT' can be a safe, effective and affordable option for patients with less severe HF in functional class I-II.</p>
      <p>In a recent publication, Guazzi et al<sup>23</sup> studied 253 patients diagnosed with HF, targeting the clinical and prognostic comparison between cardiopulmonary and six-minute walk tests. The authors confirmed the 6MWT' to be a simple and reliable tool for quantification of exercise intolerance in HF patients, however, they consider that more evidence is needed to recommend the use of the 6MWT' as an alternative prognostic marker in isolation or in combination with other variables derived from the CPET.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>Our results lead us to conclude that, when applied to patients with heart failure in non-advanced functional class (NYHA FC I-II), the 6MWT' is a method of high reproducibility, and exhibits good correlation with the variables measured in the cardiopulmonary exercise testing.</p>
      <p>Thus, our results suggest that the 6MWT' is a suitable, safe and affordable alternative for the prescription of aerobic exercise in patients with heart failure in non-advanced functional class.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was funded by FAEPA, CAPES, CNPq an FAPESP.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Insuficiencia card&#237;aca: comparaci&#243;n entre el test de esfuerzo de seis minutos y el test cardiopulmonar</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La insuficiencia card&#237;aca cr&#243;nica (IC), es un s&#237;ndrome complejo que se caracteriza por la reducci&#243;n del d&#233;bito card&#237;aco con relaci&#243;n a las necesidades metab&#243;licas del organismo, como tambi&#233;n por las alteraciones metab&#243;licas y del eje neuro hormonal. Los s&#237;ntomas como el cansancio muscular y la disnea son notables y los test de esfuerzo son ampliamente utilizados para la evaluaci&#243;n de la capacidad funcional, pron&#243;stico y eficacia de las intervenciones terap&#233;uticas en ese s&#237;ndrome. OBJETIVO: Evaluar la reproductibilidad del test de esfuerzo de seis minutos (TE6') en pacientes con IC y correlacionar la magnitud de las variables alcanzadas en el pico del esfuerzo del TE6' con las de un test cardiopulmonar (TECP). M&#201;TODOS: Se estudiaron 16 pacientes (12 hombres y 4 mujeres) con un diagn&#243;stico de IC CF I-II (NYHA). Los voluntarios se sometieron a dos test TE6' (TC6'1 y TC6'2), con un intervalo de 30 minutos entre ellos. Posteriormente realizaron un TECP m&#225;ximo. RESULTADOS: Todas las variables obtenidas en los dos TE6' fueron significativas, y con altas correlaciones: distancia recorrida (DR) (r = 0,93; p &lt; 0,0001), frecuencia card&#237;aca (FC) (r = 0,89; p &lt; 0,0001), consumo de ox&#237;geno (VO2) (r = 0,93; p &lt; 0,0001) y escala de percepci&#243;n de esfuerzo (r = 0,85; p &lt; 0,0001). A su vez, todas las variables analizadas en el TE6' mostraron correlaciones moderadas y significativas con las variables obtenidas en el TECP, a saber: FC pico (r = 0,66; p = 0,005); VO2 (r = 0,57; p = 0,02) y VO2 en el TECP y DR en el TE6'2 (r = 0,70; p = 0,002). CONCLUSI&#211;N: El TE6' se pudo reproducir en ese grupo de pacientes con IC (NYHA - I-II) y se correlacion&#243; con el TECP. Por lo tanto, se presenta como una herramienta de evaluaci&#243;n fidedigna y constituye una alternativa adecuada, segura y de bajo coste para la prescripci&#243;n de ejercicios f&#237;sicos aer&#243;bicos en pacientes con IC.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Insuficiencia card&#237;aca</kwd>
        <kwd>ejercicio</kwd>
        <kwd>esfuerzo</kwd>
        <kwd>test de funci&#243;n respiratoria</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Insuficiencia card&#237;aca: comparaci&#243;n entre el test de esfuerzo de seis minutos y el test cardiopulmonar</bold>
          </label>
          <p>
            <bold>Eduardo Elias Vieira de Carvalho<sup>I</sup>; Daniela Caetano Costa<sup>I</sup>; J&#250;lio C&#233;sar Cresc&#234;ncio<sup>I</sup>; Giovani Luiz De Santi<sup>I</sup>; Val&#233;ria Papa<sup>I</sup>; Fabiana Marques<sup>I</sup>; Andr&#233; Schmidt<sup>II</sup>; Jos&#233; Antonio Marin-Neto<sup>II</sup>; Marcus Vin&#237;cius Sim&#245;es<sup>II</sup>; Louren&#231;o Gallo Junior<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Laborat&#243;rio de Fisiologia do Exerc&#237;cio - Departamento de Cl&#237;nica M&#233;dica - Divis&#227;o de Cardiologia - Faculdade de Medicina de Ribeir&#227;o Preto - USP, Ribeir&#227;o Preto, SP - Brasil</p>
      <p><sup>II</sup>Departamento de Cl&#237;nica M&#233;dica - Divis&#227;o de Cardiologia - Faculdade de Medicina de Ribeir&#227;o Preto - USP, Ribeir&#227;o Preto, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> La insuficiencia card&#237;aca cr&#243;nica (IC), es un s&#237;ndrome complejo que se caracteriza por la reducci&#243;n del d&#233;bito card&#237;aco con relaci&#243;n a las necesidades metab&#243;licas del organismo, como tambi&#233;n por las alteraciones metab&#243;licas y del eje neuro hormonal. Los s&#237;ntomas como el cansancio muscular y la disnea son notables y los test de esfuerzo son ampliamente utilizados para la evaluaci&#243;n de la capacidad funcional, pron&#243;stico y eficacia de las intervenciones terap&#233;uticas en ese s&#237;ndrome.</p>
      <p><bold>OBJETIVO:</bold> Evaluar la reproductibilidad del test de esfuerzo de seis minutos (TE6') en pacientes con IC y correlacionar la magnitud de las variables alcanzadas en el pico del esfuerzo del TE6' con las de un test cardiopulmonar (TECP).</p>
      <p><bold>M&#201;TODOS:</bold> Se estudiaron 16 pacientes (12 hombres y 4 mujeres) con un diagn&#243;stico de IC CF I-II (NYHA). Los voluntarios se sometieron a dos test TE6' (TC6'1 y TC6'2), con un intervalo de 30 minutos entre ellos. Posteriormente realizaron un TECP m&#225;ximo.</p>
      <p><bold>RESULTADOS:</bold> Todas las variables obtenidas en los dos TE6' fueron significativas, y con altas correlaciones: distancia recorrida (DR) (r = 0,93; p &lt; 0,0001), frecuencia card&#237;aca (FC) (r = 0,89; p &lt; 0,0001), consumo de ox&#237;geno (VO<sub>2</sub>) (r = 0,93; p &lt; 0,0001) y escala de percepci&#243;n de esfuerzo (r = 0,85; p &lt; 0,0001). A su vez, todas las variables analizadas en el TE6' mostraron correlaciones moderadas y significativas con las variables obtenidas en el TECP, a saber: FC pico (r = 0,66; p = 0,005); VO<sub>2</sub> (r = 0,57; p = 0,02) y VO<sub>2</sub> en el TECP y DR en el TE6'2 (r = 0,70; p = 0,002).</p>
      <p><bold>CONCLUSI&#211;N:</bold> El TE6' se pudo reproducir en ese grupo de pacientes con IC (NYHA - I-II) y se correlacion&#243; con el TECP. Por lo tanto, se presenta como una herramienta de evaluaci&#243;n fidedigna y constituye una alternativa adecuada, segura y de bajo coste para la prescripci&#243;n de ejercicios f&#237;sicos aer&#243;bicos en pacientes con IC. (Arq Bras Cardiol 2011; 97(1):59-64)</p>
      <p><bold>Palabras clave:</bold> Insuficiencia card&#237;aca, ejercicio, esfuerzo, test de funci&#243;n respiratoria.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia card&#237;aca cr&#243;nica (IC), es el camino final com&#250;n para la mayor&#237;a de las cardiopat&#237;as. Se trata de un s&#237;ndrome cl&#237;nico complejo, caracterizado por la incapacidad del coraz&#243;n de generar d&#233;bito card&#237;aco a niveles capaces de atender a las necesidades metab&#243;licas del organismo<sup>1</sup>, asociado a disturbios metab&#243;licos, inflamatorios y a la activaci&#243;n neuro-hormonal<sup>2</sup>. Representa un importante problema en la salud p&#250;blica, teniendo en cuenta la prevalencia in crescendo y los &#237;ndices de hospitalizaci&#243;n asociados a la alta morbimortalidad. Los avances cient&#237;ficos y tecnol&#243;gicos y las mejores condiciones socioecon&#243;micas han propiciado un aumento de la longevidad de la poblaci&#243;n en general y tambi&#233;n de los cardi&#243;patas, factor asociado al acentuado aumento de la incidencia de IC en Brasil y en el mundo<sup>3</sup>.</p>
      <p>Por regla general, los pacientes con IC tienen una exacerbaci&#243;n de los s&#237;ntomas durante el esfuerzo y la medida de la tolerancia al ejercicio se utiliza para evaluar su capacidad funcional, que se correlaciona con la gravedad de la disfunci&#243;n card&#237;aca. As&#237;, el uso del test de esfuerzo para la mensuraci&#243;n objetiva de la capacidad funcional es un valioso instrumento para la estratificaci&#243;n del pron&#243;stico de los pacientes con insuficiencia card&#237;aca<sup>4,5</sup>. En ese sentido, el test de esfuerzo cardiopulmonar (TECP), ha sido establecido como el est&#225;ndar de referencia.</p>
      <p>El test de esfuerzo de seis minutos (TE6') por su amplia disponibilidad, seguridad y facilidad en su ejecuci&#243;n, est&#225; siendo cada vez m&#225;s utilizado como una alternativa al TECP para evaluar la capacidad funcional de pacientes con IC<sup>5-8</sup>. Se le considera un esfuerzo subm&#225;ximo que mimetiza las actividades diarias y generalmente es bien tolerado por los pacientes. Es interesante destacar que la distancia recorrida durante el TE6' es un predictor independiente de mortalidad y de nuevos ingresos en pacientes con IC<sup>3,9,10</sup>. Por a&#241;adidura, el aumento de la distancia recorrida en seis minutos ha parecido un &#237;ndice sensible para evaluar la respuesta a intervenciones terap&#233;uticas en la IC<sup>11</sup>.</p>
      <p>Pese a su extensa utilizaci&#243;n, todav&#237;a existen controversias sobre si los resultados obtenidos en el TE6' presentan una adecuada correlaci&#243;n con aquellos originados del TECP, en pacientes con un nivel de gravedad diferente del s&#237;ndrome de IC<sup>12</sup>. Por tanto, el objetivo del presente estudio fue evaluar la reproductibilidad del TE6' y comparar los resultados de los &#237;ndices de evaluaci&#243;n de la capacidad funcional obtenidos en el TE6' con los del TECP, en pacientes con IC cr&#243;nica no avanzada.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>Los pacientes incluidos en este estudio fueron seleccionados a partir de la casu&#237;stica de un proyecto anteriormente realizado en nuestra instituci&#243;n, y cuyo objetivo principal fue evaluar la reserva contr&#225;ctil en pacientes con IC de etiolog&#237;a no isqu&#233;mica. En aqu&#233;l estudio original se investigaron prospectivamente 30 pacientes con IC clase funcional I - III (NYHA). Los pacientes estaban cl&#237;nicamente estables y bajo el uso de terapia medicamentosa debidamente optimizada, con el acompa&#241;amiento cl&#237;nico ambulatorial en la cl&#237;nica de IC de nuestra instituci&#243;n. Entre esos pacientes, fueron identificados aquellos cuyos datos existentes de los TECP y TE6' pudieron ser recuperados en los respectivos sistemas de procesamiento y an&#225;lisis. De esa forma, se identificaron 16 pacientes (12 hombres y 4 mujeres), con edad promedio (&#177;DR) de 57,5 (&#177; 10,1) a&#241;os, y diagn&#243;stico de IC clase funcional I-II (NYHA). Todos hab&#237;an participado voluntariamente en el estudio, cuyas principales caracter&#237;sticas antropom&#233;tricas, cl&#237;nicas y laboratoriales aparecen en la <xref ref-type="table" rid="tab1-body3">tabla 1</xref>.</p>
      <table-wrap id="tab1-body3">
        <graphic xlink:href="1678-4170-abc-97-01-0059-00056-gt01-es.jpg"/></table-wrap>
      <p>En el momento de la realizaci&#243;n de los test, todos firmaron el T&#233;rmino de Consentimiento Informado, y el estudio fue aprobado por el Comit&#233; de &#201;tica en Investigaci&#243;n del HCFMRP - USP.</p>
      <p>
        <bold>Test de esfuerzo y Test cardiopulmonar</bold>
      </p>
      <p>Despu&#233;s de una evaluaci&#243;n cl&#237;nica y juiciosa, y de la inclusi&#243;n en el estudio, los pacientes realizaron primeramente el TE6' y en el plazo m&#225;ximo de una semana, se sometieron al TECP. Esa ventana temporal estrecha tiene el objeto de limitar la eventual influencia de cambios del estado cl&#237;nico y de la gravedad de los s&#237;ntomas sobre los resultados de los tests de evaluaci&#243;n de la capacidad funcional. Todos los test fueron realizados en el per&#237;odo de la ma&#241;ana para estandarizar las influencias de las variaciones circadianas de la frecuencia card&#237;aca (FC) y de las restantes variables cardiorrespiratorias.</p>
      <p>Los TE6' fueron aplicados por los mismos examinadores en un pasillo de 30 metros, con marcas a cada 5 metros, para la exacta determinaci&#243;n de la distancia recorrida<sup>13</sup>. Los pacientes fueron monitorizados por el medidor de frecuencia cardiaca Polar<sup>&#174;</sup> S810, con registro instant&#225;neo y el almacenaje de los valores de FC. Los valores de la presi&#243;n arterial fueron obtenidos por el m&#233;todo auscultatorio (esfigmoman&#243;metro aneroide) antes del test, e inmediatamente despu&#233;s de su finalizaci&#243;n, en el segundo y en el cuarto minutos de recuperaci&#243;n, y el &#237;ndice de percepci&#243;n de la intensidad de esfuerzo de Borg (CR10), se obtuvo al comienzo y al final del test. La FC pico se obtuvo en el an&#225;lisis posterior de los datos almacenados por el <italic>software</italic> POLAR<sup>&#174;</sup> Precision Performance SW.</p>
      <p>Los pacientes fueron orientados a caminar a una velocidad m&#225;xima durante los seis minutos del test (TE6'1); y si fuese necesario, tambi&#233;n podr&#237;an parar para descansar y enseguida retomar el test. Los examinadores les hablaron con frases de incentivo para que los pacientes mantuviesen el mismo ritmo de esfuerzo hasta el final del test, y al final de seis minutos fue medida la distancia recorrida (DR). Despu&#233;s de un intervalo m&#237;nimo de 30 minutos y m&#225;ximo de 45 minutos, los pacientes repitieron el test de esfuerzo (TE6'2), secundando el mismo m&#233;todo.</p>
      <p>El c&#225;lculo del consumo de ox&#237;geno (VO<sub>2</sub>) estimado para el test de esfuerzo fue realizado mediante una f&#243;rmula publicada anteriormente<sup>10</sup>.</p>
      <p>Todos los voluntarios estudiados se sometieron a una prueba ergoespirom&#233;trica m&#225;xima. El protocolo consisti&#243; en la realizaci&#243;n de esfuerzo f&#237;sico din&#225;mico en posici&#243;n sentado, en cicloerg&#243;metro de freno electromagn&#233;tico (Corival 400, Quinton). La potencia aplicada al cicloerg&#243;metro fue del tipo rampa, con una intensidad determinada seg&#250;n una f&#243;rmula desarrollada por Wasserman et al<sup>14</sup>, con base en las caracter&#237;sticas antropom&#233;tricas, en la edad y en el sexo. Los pacientes fueron motivados a realizar el esfuerzo aplicado hasta la potencia en que alcanzasen el agotamiento cardiorrespiratorio. En todos los pacientes estudiados, el inicio de la rampa fue precedido de un esfuerzo con carga m&#237;nima (3-4 Watts) a una velocidad constante de 60 rotaciones por minuto, con el objetivo de obtener un calentamiento previo de los sistemas fisiol&#243;gicos involucrados en el transporte de ox&#237;geno. Las variables ventilatorias se obtuvieron en ese protocolo usando un ergoespir&#243;metro (CPX/D MedGraphics) que permite la adquisici&#243;n, el procesamiento y el almacenaje de los datos de respiraci&#243;n a respiraci&#243;n. Los valores pico de VO<sub>2</sub> y de FC se expresaron como promedio de los &#250;ltimos 30 segundos de registro, y fueron los escogidos para ser comparados con la distancia recorrida y el VO<sub>2</sub> inferido en el TE6'.</p>
      <p>Para el an&#225;lisis de la correlaci&#243;n entre el TE6' y el TECP, se opt&#243; por utilizar el TE6'2, una vez que, en el segundo test, se espera que los pacientes est&#233;n m&#225;s bien familiarizados con la metodolog&#237;a y puedan realizarlo con un mejor dominio y seguridad en la t&#233;cnica.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Los datos se expresaron en valores promedio &#177; desviaci&#243;n est&#225;ndar. El an&#225;lisis estad&#237;stico fue realizado usando el test no param&#233;trico de correlaci&#243;n de Spearman. El nivel de significancia estad&#237;stica fue de un 5%.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Los datos de correlaci&#243;n entre los TE6'1 y TE6'2 aparecen en la figura 1. La DR mostr&#243; un valor del coeficiente de correlaci&#243;n alto y estad&#237;sticamente significativo entre TE6'1 y TE6'2 (545,47 &#177; 74,49 m y 550,31 &#177; 66,40 m, respectivamente) (r = 0,93; p &lt; 0,0001, <xref ref-type="fig" rid="es_a10fig1-body3">figura 1A</xref>). La respuesta de la FC pico, medida por el medidor de frecuencia cardiaca al final del sexto minuto de cada test (128 &#177; 24 lpm para TE6'1 y 129 &#177; 25 lpm para TE6'2), tambi&#233;n present&#243; una correlaci&#243;n significativa (r = 0,89; p &lt; 0,0001, <xref ref-type="fig" rid="es_a10fig1-body3">figura 1B</xref>). De forma similar, el VO<sub>2</sub> pico, estimado en los TE6'1 y TE6'2 (20,34 &#177; 2,23 ml/kg/min; 20,49 &#177; 1,99 ml/kg/min, respectivamente), present&#243; valor de correlaci&#243;n alto y significativo (r = 0,93; p &lt; 0,0001, <xref ref-type="fig" rid="es_a10fig1-body3">figura 1C</xref>). Finalmente, la intensidad de percepci&#243;n del esfuerzo al final de cada test (4,5 &#177; 1,7 y 4,8 &#177; 1,7 para TE6'1 y TE6'2, respectivamente) evaluado por la escala de Borg, tambi&#233;n mostr&#243; una alta y significativa correlaci&#243;n (r = 0,85; p &lt; 0,0001, <xref ref-type="fig" rid="es_a10fig1-body3">figura 1D</xref>).</p>
      <p content-type="html"><fig id="es_a10fig1-body3"><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/5x4NjhJCQ9fZpKDMQSpb7Ms/2efe32bb9edf046c63b1e6314348b95e831854ff.jpg"/><graphic xlink:href="1678-4170-abc-97-01-0059-00056-gf01-es.jpg"/></fig>&#13;
&#160;&#13;
</p>
      <p>La <xref ref-type="fig" rid="es_a10fig2-body3">figura 2</xref> muestra los par&#225;metros correlacionados entre el TE6'2 y el TECP. La relaci&#243;n de la FC pico del TE6'2 y del TECP (129 &#177; 25 lpm y 122 &#177; 24 lpm, respectivamente), muestra un valor del coeficiente de correlaci&#243;n moderado m&#225;s significativa (r = 0,66; p = 0,005, <xref ref-type="fig" rid="es_a10fig2-body3">figura 2A</xref>). La relaci&#243;n del VO<sub>2</sub> pico estimado en el TE6'2, a trav&#233;s de la f&#243;rmula consagrada en la literatura<sup>10</sup> y en el TECP por medio del an&#225;lisis directo de los gases espirados (20,49 &#177; 1,99 ml/kg/min para TE6'2 y 14,12 &#177; 4,11 ml/kg/min para TECP), arroja un valor moderado de correlaci&#243;n, pero significativo (r = 0,57; p = 0,02, <xref ref-type="fig" rid="es_a10fig2-body3">figura 2B</xref>). En resumen, el an&#225;lisis de la relaci&#243;n entre la DR en el TE6'2 y el VO<sub>2</sub> pico obtenido en el TECP (550,31 &#177; 66,40 m y 1.025,25 &#177; 332,13 ml/min), arroja un valor moderado y significativo del coeficiente de correlaci&#243;n (r = 0,70; p = 0,002, <xref ref-type="fig" rid="es_a10fig2-body3">figura 2C</xref>).</p>
      <p content-type="html"><fig id="es_a10fig2-body3"><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/5x4NjhJCQ9fZpKDMQSpb7Ms/faa3f7a0716a3c6275b42cd0d5c40afeeaec2f83.jpg"/><graphic xlink:href="1678-4170-abc-97-01-0059-00056-gf02-es.jpg"/></fig>&#13;
&#160;&#13;
</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La evaluaci&#243;n de la capacidad subm&#225;xima de esfuerzo a trav&#233;s del TE6' ha venido siendo incorporada a la pr&#225;ctica cl&#237;nica para pacientes con IC en raz&#243;n de su f&#225;cil aplicaci&#243;n, el bajo coste y la seguridad. Ese test pareci&#243; ser &#250;til y confiable para la evaluaci&#243;n de la capacidad funcional, el pron&#243;stico y la eficacia terap&#233;utica de pacientes con ese s&#237;ndrome<sup>5,8,9,15</sup>.</p>
      <p>Uno de los objetivos de este estudio fue analizar la reproductibilidad de la aplicaci&#243;n del TE6' en la IC, mediante la realizaci&#243;n de dos test de secuencia para el mismo paciente. Sobre ese aspecto, nuestros datos nos dicen que el an&#225;lisis de las variables DR, FC, VO<sub>2</sub> y percepci&#243;n de esfuerzo medidas en los dos test de esfuerzo de seis minutos, tuvieron una fuerte correlaci&#243;n, evidenciando su reproductibilidad. A modo de consenso, la mayor&#237;a de los trabajos encontrados en la literatura, han venido siendo utilizados en la aplicaci&#243;n de m&#225;s de un test para determinar la distancia recorrida, ya que ese procedimiento puede mejorar la familiarizaci&#243;n de la t&#233;cnica por parte del paciente<sup>5,8,12</sup>. Corroborando nuestros hallazgos, Cahalin et al<sup>10</sup> comprobaron la reproductibilidad del TE6' en 20 pacientes y encontraron un valor del coeficiente de correlaci&#243;n intra-clase estimado de un 0,96.</p>
      <p>El test de esfuerzo cardiopulmonar ha sido extensamente usado en la mensuraci&#243;n objetiva del VO<sub>2</sub> y hoy por hoy, se le considera como el est&#225;ndar de referencia en la evaluaci&#243;n de la capacidad funcional<sup>16,17</sup>. &#201;l ha sido muy utilizado como pronosticador de morbimortalidad en pacientes con IC, como fue demostrado por Gitt et al<sup>18</sup> en un estudio con 223 pacientes portadores de IC, en que demostraron que el grupo de pacientes con VO<sub>2</sub> pico <underline>&lt;</underline> 14 ml/kg/min, o VO<sub>2</sub> en el l&#237;mite de anaerobiosis &lt; 11 ml/kg/min, presentaba un mayor riesgo de muerte. Sin embargo, esa t&#233;cnica presenta un alto coste, necesita un equipamiento sofisticado, una mano de obra especializada y solamente se le encuentra en determinados centros<sup>5</sup>. Adem&#225;s, necesita una mayor colaboraci&#243;n por parte del paciente.</p>
      <p>En la presente muestra estudiada, el promedio del VO<sub>2</sub> pico obtenido por la medida directa en el TECP fue de 14,12 &#177; 4,11 ml/kg/min. Cuando ese promedio fue correlacionado con el promedio obtenido por medio de la medida indirecta en el TE6' (20,49 &#177; 1,99 ml/kg/min) observamos que, pese a que la f&#243;rmula utilizada para el c&#225;lculo del VO<sub>2</sub> en el TE6' supervalore el real valor de la medida del VO<sub>2</sub> pico, una correlaci&#243;n moderada entre ellas se registr&#243;. Usando la misma f&#243;rmula, Cahalin et al<sup>10</sup> tambi&#233;n mostraron que en pacientes con IC exist&#237;a una correlaci&#243;n lineal entre el VO<sub>2</sub> pico en el TE6' y en el TECP.</p>
      <p>Una variable de gran importancia en la evaluaci&#243;n del pron&#243;stico del TE6' en pacientes con IC es la m&#225;xima DR. Algunos estudios han demostrado que un valor menor o igual a 300 metros en seis minutos indica un peor pron&#243;stico, en comparaci&#243;n con los pacientes que recorren m&#225;s de 300 metros<sup>10,19</sup>. Nuestro trabajo pudo demostrar que dos variables cr&#237;ticas, la DR en el TE6' y el VO<sub>2</sub> pico en el TECP, presentan una correlaci&#243;n a nivel moderado y estad&#237;sticamente significativa en el pico del esfuerzo en pacientes con IC de clase funcional I - II (r = 0,70; p = 0,002). Estudios anteriores<sup>10,17</sup> confirman nuestros resultados mostrando una buena correlaci&#243;n entre los resultados del TE6' y del TECP<sup>12,20,21</sup>. En una muestra de 26 pacientes con IC (NYHA II - IV) Faggiano et al<sup>20</sup> encontraron una significativa correlaci&#243;n entre la DR en el TE6' y el VO<sub>2</sub> pico alcanzado en el TECP (r = 0,63).</p>
      <p>Los resultados relatados en la literatura, sin embargo, no son homog&#233;neos. En el estudio de Lucas et al<sup>12</sup>, hecho con 307 pacientes con IC avanzada (fracci&#243;n de eyecci&#243;n &lt; 35%), el VO<sub>2</sub> pico que se obtuvo en el TECP s&#237;ntoma limitado, aplicado y a un subgrupo de 213 pacientes con VO<sub>2</sub> pico entre 10 - 20 ml/kg/min, arroj&#243; una baja correlaci&#243;n con la DR en el TE6' (r = 0,28). En otro estudio de Roul et al<sup>19</sup> tambi&#233;n hecho en 121 pacientes con IC (clases funcionales NYHA- II - III, fracci&#243;n de eyecci&#243;n 29,6% &#177; 13%) se demostr&#243; una baja correlaci&#243;n entre VO<sub>2</sub> pico en el TECP s&#237;ntoma limitado y DR en el TE6' (r = 0,24).</p>
      <p>El principal factor responsable de la aparente discrepancia entre nuestros resultados y los de otros investigadores, en contraposici&#243;n con los resultados obtenidos en los estudios citados anteriormente, puede residir en las caracter&#237;sticas de la poblaci&#243;n estudiada en cada estudio, particularmente en la gravedad de la IC. Por lo tanto, podemos suponer que, en las poblaciones con IC avanzada (CF III-IV), la correlaci&#243;n entre TECP y TE6' sea menor. Reforzando esa hip&#243;tesis, en el estudio de Lucas et al<sup>12</sup>, la aplicaci&#243;n del an&#225;lisis de correlaci&#243;n no restricto a los pacientes m&#225;s graves result&#243; en mejores niveles de correlaci&#243;n (r = 0,52).</p>
      <p>El aparecimiento del comportamiento lineal entre las respuestas de la FC y del VO<sub>2</sub><sup>21</sup> durante el ejercicio f&#237;sico din&#225;mico, nos ha suministrado las bases para la aplicaci&#243;n de m&#233;todos indirectos de evaluaci&#243;n de la reserva funcional para la prescripci&#243;n de ejercicio f&#237;sico y su uso en test de esfuerzo que no poseen la medida directa del consumo de ox&#237;geno. Comparando la FC pico alcanzada con los TECP y TE6', pudimos observar una moderada pero significativa correlaci&#243;n (r = 0,66; p = 0,005). Teniendo en cuenta que la respuesta cronotr&#243;pica fue similar en los dos test, ese hallazgo adquiere importancia, visto que el TE6' es un m&#233;todo de evaluaci&#243;n bastante sencillo y accesible. Resaltemos que, de acuerdo con el I&#186; Consenso Nacional de Rehabilitaci&#243;n Cardiovascular<sup>22</sup>, para que la prescripci&#243;n de actividad f&#237;sica sea realizada de forma segura y adecuada, la mejor manera ser&#237;a usando la FC pico que se obtiene en un test de esfuerzo limitado por s&#237;ntomas.</p>
      <p>Creemos que a partir de los actuales resultados, la prescripci&#243;n del ejercicio f&#237;sico por la utilizaci&#243;n del TE6' puede ser una opci&#243;n segura, eficaz y de bajo coste en pacientes con IC menos grave, en clase funcional I-II.</p>
      <p>En una reciente publicaci&#243;n, Guazzi et al<sup>23</sup> estudiaron a 253 pacientes con diagn&#243;stico de IC, objetivando la comparaci&#243;n cl&#237;nica y el pronostico entre los test cardiopulmonar y de esfuerzo de seis minutos. Los autores confirmaron que el TE6' es una herramienta confiable y sencilla para la cuantificaci&#243;n de la intolerancia al esfuerzo en pacientes con IC, pero, al mismo tiempo consideran que se hacen necesarias m&#225;s pruebas para recomendar la utilizaci&#243;n del TE6' como un marcador de pron&#243;stico alternativo aislado o asociado a otras variables derivadas del TECP.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Nuestros resultados nos llevan a concluir que, cuando se aplica a los pacientes con IC en clase funcional no avanzada (CF NYHA I-II), el TE6' es un m&#233;todo de elevada reproductibilidad y que presenta una buena correlaci&#243;n con las variables medidas en el test cardiopulmonar.</p>
      <p>Por lo tanto, nuestros resultados sugieren que el TE6' constituye una alternativa adecuada, segura y de bajo coste para la prescripci&#243;n de ejercicios f&#237;sicos aer&#243;bicos en pacientes con IC en clase funcional no avanzada.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>FAEPA, CAPES, CNPq y FAPESP financiaron el presente estudio.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
